Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,455 Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001
N/A N=32 Artificial Pancreas in Pediatric Patients (PEDarPAN)
Type 1 Diabetes
Primary: Percentage of Time Spent With Blood Glucose < 3.9 mmol/L (or 70 mg/dl) — 2; 6.7 percentage
N/A N=28 Ankle-foot Orthoses for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units
Phase 2 N=39 Hepatocyte Growth Factor to Improve Functioning in PAD
Peripheral Artery Disease
Primary: Six-minute Walk Distance — 17.01; 3.46 meters — p=0.7586
N/A N=23 Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT)
Post Thrombotic Syndrome · Deep Vein Thrombosis
Primary: Feasibility as Measured by Number of Participants Who Meet Study Eligibility Criteria at Baseline — 40 Participants
N/A N=55 FORWARD PAD IDE Study With the Shockwave Javelin IVL Catheter
Peripheral Arterial Disease
Primary: Primary Safety Endpoint - Major Adverse Events (MAE) at 30 Days — 0; 0; 0; 0 participants
Phase 2 N=46 3 Month PHI PAD PoM Study
Vascular Disease, Peripheral
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 14; 6; 9; 3 Participants
N/A N=16 PACT (Platelet Activity After Clopidogrel Termination)
Blood Platelets · Clopidogrel
Primary: Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention. — 123.2; 126.7 mean fluorescence intensity (MFI)
N/A N=347 Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.
Peripheral Arterial Disease
Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters
N/A N=21 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
Phase 2 N=61 Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 514.6; 512.0 dyn*sec/cm^5 — p=0.0220
N/A N=172 The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions
Peripheral Artery Disease
Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants
N/A N=1,000 ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial
Radiation Exposure
Primary: Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator — 6.41; 3.51 10,000 x uSv / mGy*cm^2
N/A N=150 IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Primary Patency — 82.2; 52.4 Percentage of participants — p=<0.001
Phase 1 N=6 A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
Peripheral Arterial Disease · Intermittent Claudication
Primary: Change in Six-minute Walk Distance — 32.3 Meters
N/A N=246 P3 (Prepared, Protected, emPowered)
Sexually Transmitted Diseases · Safe Sex · Adherence, Medication
Primary: PrEP Adherence Defined by Tenofovir Diphosphate (P3 and P3+ vs Control) — 24; 33; 23; 18 Participants — p=0.04965
Phase 2 N=16 Paediatric Safety Study in Cat-PAD
Rhinoconjunctivitis
Primary: Number of Subjects With AEs — 5; 12 participants
N/A N=33 Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis
Peripheral Artery Disease
Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds
Phase 2 N=203 Edoxaban in Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants
N/A N=604 Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
N/A N=102 The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
Type 1 Diabetes
Primary: Time in Range — 56.7; 54.9; 69.3; 55.9 Percent of time — p=<0.001
N/A N=607 The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs — 6; 4 Participants
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
Phase 3 N=1,408 Phase III Cat-PAD Study
Rhinoconjunctivitis
Primary: Mean Combined Score in Cat-PAD Treatment Groups Compared With Placebo — 1.04; 1.00; 1.05 units on a scale
N/A N=20 Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in the Mean Daily Walking Distance Over 7 Consecutive Days — 754.2; -1160 steps
N/A N=10 Improving Walking in Peripheral Artery Disease
Peripheral Artery Disease
Primary: Changes in Walking Distance After Three-months Intervention — 289.68; 262.95 meters
N/A N=1,204 Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
Peripheral Arterial Occlusive Disease
Primary: Procedural Success of Endovascular PAD Treatment(s) — 83.6; 75.8; 68.5 percent of procedures
Phase 4 N=102 Electrophysiologically Guided PAcing Site Selection Study
Sinus Arrhythmia · Atrial Fibrillation
Primary: Number of Patients With Persistent Atrial Fibrillation (AF) After a Mean Follow-up of 15±7 Months: Comparison Between IAS and RAA Pacing in the Study Group — 2; 2; 9; 2…
N/A N=200 Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)
Appendicitis · Children
Primary: Decision Self-Efficacy Scale — 100; 100 units on a scale — p=0.03